Logo von

News and Events

Development of rapid novel SARS-CoV-2 diagnostics started

Enzyme specialists from EUCODIS Bioscience and diagnostics experts from Biosynth-Carbosynth have teamed up to develop a novel diagnostic tool for the fast and reliable detection of an acute SARS-CoV-2 infection.


Based on viral enzymatic activities and a novel enzymatic bioluminescence substrate, the diagnostic test should identify active as well as asymptomatic early infections within minutes – which would be a tremendous help in the fight against the SARS-CoV-2 pandemic.


In an acute…

More Information

Note on COVID-19: Operations without major disruptions at EUCODIS

With regard to the current situation concerning COVID-19 in Austria Eucodis reacted promptly and implemented preventive measures to minimize the impact of COVID-19-related disruptions on our business. We are currently running our operations without major disruptions and are striving to continue to do so.


We are monitoring the COVID-19 situation and adapt our lean organization continuously to make sure development timelines are being met and products will be delivered on time. We will provide…

More Information

Scientists from EUCODIS contributed to research published in Nature Catalysis

Improving biocatalytical processes through genetically engineering proteins is one great challenge in today’s biotechnological industry. One new approach regarding this is engineering multiple active sites - both from biological and abiological origin - into one protein. A team around Manuel Ferrer from the Institute of Catalysis in Madrid, Spain together with two members from the research department of EUCODIS have mastered this challenge and could publish their results in the current issue of…

More Information

Novel Catalase for complete neutralization of hydrogen peroxide in agar plates

EUCODIS Bioscience, an established Austrian enzyme engineering and manufacturing company, developed and patented a catalase as a novel neutralizer in environmental monitoring media and offers either a collaboration or OEM supply of the enzyme or the technology itself for licensing.

EUCODIS Bioscience’s patented recombinant catalase formulation is unique as it is the only one worldwide that can be applied to agar plates due to its increased stability at high temperatures (stable at 55°C during…

More Information

ChitoTex and Eucodis Bioscience: Enzyme development for chitosan production

Within the ChitoTex project EUCODIS Bioscience, the Fraunhofer IGB, the Norwegian University of Life Sciences (NMBU) and others collaborated to establish a new enzyme based approach to produce chitosan for the treatment of textile fibers and yarns in a more sustainable way. EUCODIS played an important role in the screening and modification of those enzymes aiming to develop suitable expression systems as well as efficient, stable, recombinant enzymes to produce chitosan.

The Fraunhofer IGB laid…

More Information

EUCODIS Bioscience developed enzyme and enzymatic production method for PrEP Biopharm drug intermediate

EUCODIS Bioscience, an Austrian biotechnology company with strong expertise in industrial enzyme development, announces the completion of a development project for PrEP Biopharm Limited. In this collaboration, EUCODIS Bioscience developed an enzymatic method for production of a drug intermediate of PrEP-001, an immunomodulator for the prevention of the common cold and influenza and supplied key consumables for the GMP manufacturing process.

PrEP Biopharm Limited is a U.K.-based clinical stage,…

More Information

Eucodis starts commercialization of tubulysin A and B

Eucodis Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and Eucodis now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.

Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production…

More Information

Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

An anti-Her2 antibody conjugated to the maytansinoid DM1 using the novel CTATTM-linker technology (“CTAT-ADC”) was tested in nude mice with SKOV-3 cancer cell xenografts for maximum tolerated dose (“MTD”) and…

More Information



CpHI worldwide

13 - 15 October 2020
Milan, Italy

BioEurope 2020

26 - 28 October 2020
Munich, Germany